Scientific article
OA Policy
English

Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal study

Published in

Arthritis research & therapy, vol. 17, 151

Publication date

2015

Abstract

Patients undergoing immunosuppressive therapy are at increased risk of infection. Community-acquired pneumonia and invasive pneumococcal disease account for substantial morbidity and mortality in this population and may be prevented by vaccination. Ideally, immunization to pneumococcal antigens should take place before the start of immunosuppressive treatment. Often, however, the treatment cannot be delayed. Little is known about the efficacy of pneumococcal vaccines during immunosuppressive treatment. The objectives of this study were to determine the percentage of vaccine-naïve, immunosuppressed adults with inflammatory diseases seroprotected against Streptococcus pneumoniae and to assess factors associated with the immunogenicity, clinical impact and safety of 23-valent pneumococcal polysaccharide vaccine (PPV) in seronegative subjects.

Citation (ISO format)

FISCHER, Lara et al. Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal study. In: Arthritis research & therapy, 2015, vol. 17, p. 151. doi: 10.1186/s13075-015-0663-9

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

1478-6354
561views
682downloads

Technical informations

Creation

16/09/2015 10:57:00

First validation

16/09/2015 10:57:00

Update

24/01/2025 14:33:10

Status update

24/01/2025 14:33:10

Last indexation

24/01/2025 14:41:14
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated